Cara Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced that its CEO, Christopher Posner, will present at two upcoming investor conferences. The H.C. Wainwright Global Investment Conference is scheduled for May 25, 2022, at 10:30 a.m. ET, followed by the Jefferies Healthcare Conference on June 8, 2022, at 3:30 p.m. ET. Investors can access webcasts of these presentations on the company's website under 'Events & Presentations.' Cara is known for its FDA-approved treatment, KORSUVA™, aimed at alleviating pruritus in patients with chronic kidney disease.

STAMFORD, Conn., May 17, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the following investor conferences:

H.C. Wainwright Global Investment Conference
Wednesday, May 25, 2022, at 10:30 a.m. ET

Jefferies Healthcare Conference
Wednesday, June 8, 2022, at 3:30 p.m. ET

Webcasts of the presentations can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 proof-of-concept trials of Oral KORSUVA (difelikefalin) are ongoing in notalgia paresthetica and primary biliary cholangitis patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

When will Cara Therapeutics present at the H.C. Wainwright Global Investment Conference?

Cara Therapeutics will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:30 a.m. ET.

What is the schedule for the Jefferies Healthcare Conference presentation by Cara Therapeutics?

Cara Therapeutics will present at the Jefferies Healthcare Conference on June 8, 2022, at 3:30 p.m. ET.

Where can I access the webcasts of Cara Therapeutics' presentations?

Webcasts of Cara Therapeutics' presentations can be accessed under 'Events & Presentations' on their official website.

What is KORSUVA™ and its significance to Cara Therapeutics?

KORSUVA™ is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease.

What ongoing developments is Cara Therapeutics pursuing with difelikefalin?

Cara Therapeutics is developing an oral formulation of difelikefalin and is conducting Phase 3 programs for treating pruritus in patients with advanced chronic kidney disease and atopic dermatitis.